Abstract
Chapter 3 focuses on introducing a case study of the stakeholder management challenges facing decision-makers in the pharmaceutical industry in the UK and Germany. It highlights the specific contextual operating dilemmas in what could be considered a highly complicated operating context. This context-specific focus establishes the complex quality of the quest to harmonise stakeholder interests in a responsible way for this sector.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
French writer, humanist and moralist, 1947 Nobel Prize in Literature, 1869–1951.
- 2.
The word ‘responsible’ is employed in this book as an adjective in the sense of being accountable. It is assumed to mean to be responsible compared with the closely related noun ‘responsibility’, which is inferred to imply the obligation or duty to have a responsibility.
- 3.
By definition, as noted in the previous section, this means that in those countries where the drugs are not covered by health insurance , access to medication is limited for those who cannot afford them.
- 4.
It may also be necessary to distinguish pharmaceutical product markets according to the mode of administration (an injectable drug may not be considered to be a substitute for an oral drug) or different distribution methods (a hospital-only drug may not act as a competitive constraint on a widely available prescription drug) (OECD, 2001, pp. 11–12).
- 5.
For clarification, the data upon which the research presented in this book is based was undertaken in the period before the Brexit referendum, and this text accordingly refers to the situation before the Brexit decision in the UK.
- 6.
Please refer to Chap. 2 for further details.
- 7.
While many health systems’ rankings have been widely criticised, such the 2000 World Health Report, according to the British Medical Journal (2016), these are far more transparent, methodologically, than the EuroHealth Consumer Index. However, similar to other complex systems, there is no universal consensus on the ‘right’ way to rank health systems.
- 8.
While this implies that citizens contribute according to their means, public sector monopoly is not implied as might be inferred in the UK.
- 9.
For clarification however, comparing the healthcare contribution rate is complex because accident insurance [Arbeitsunfallversicherung] and long-term care insurance [Pflegeversicherung] are usually bundled with health insurance by many funds.
- 10.
This section is adapted from text which originally appeared in O’Riordan (2010, pp. 44–48).
- 11.
The ABPI represents large, medium, and small, innovative research-based biopharmaceutical companies in the field of biosciences in the UK. It is recognised by the Government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
- 12.
The business activities of research-based pharmaceutical companies have been described above as developing and producing pharmaceutical products and services as therapies and diagnostics for human application/consumption aimed at enhancing the quality of life as well as to cure illness and/or save lives.
- 13.
The IFPMA quotes presented in this section were made by the Director General of the IFPMA, Dr. Harvey Balle.
- 14.
Resulting from an upsurge in connectivity related to the ease of communicating information due to improved technology, which enhances internet access and communication, leading to increased social networking.
- 15.
As a result, pharmaceutical firms have been prosecuted for anti-trust violations, including for cartels, price -fixing and forms of tying, exclusive marketing agreements, as well as agreements to delay the entry of generics.
References
ABPI. (2005). Association of British Pharmaceutical Industry. Accessed February 2005, from www.abpi.org.uk.
ABPI. (2010). Association of British Pharmaceutical Industry. Accessed June 2010, from www.abpi.org.uk.
ABPI. (2013). Corporate social responsibility. Association of the British Pharmaceutical Industry. Accessed October 2013, from http://www.abpi.org.uk/industry-info/csr/Pages/default.aspx.
Albareda, L., Lozano, J. M., Tencati, A., Midttun, A., & Perrini, F. (2008). The changing role of governments in corporate social responsibility: Drivers and responses. Business Ethics: A European Review, 17(4), 347–363.
Alpern, J. D., Stauffer, W. M., & Kesselheim, A. S. (2014). High-cost generic drugs—Implications for patients and policymakers. The New England Journal of Medicine, 371, 1869–1862. Accessed March 2016, from http://www.nejm.org/doi/full/10.1056/NEJMp1408376.
Altenstetter, C. (1987). An end to a consensus on health care in the Federal Republic of Germany? Journal of Health Politics, Policy and Law, 12(1987), 505–536.
Anderson, R. (2014). Pharmaceutical industry gets high on fat profits. BBC News. 6 November 2014. Accessed March 2016, from http://news.bbc.co.uk/2/hi/health/7149423.stm.
BBC. (2008a). Huge contrasts in devolved NHS. BBC News. 28 August 2008. Accessed March 2016, from http://news.bbc.co.uk/2/hi/health/7586147.stm.
BBC. (2008b). NHS now four different systems. BBC News. 2 January 2008. Accessed March 2016, from http://news.bbc.co.uk/2/hi/health/7149423.stm.
Blair, M. M. (1998). For whom should corporations be run? An economic rationale for stakeholder management. Long Range Planning, 32(2), 195–200.
BMJ. (2016). What, if anything, does the EuroHealth consumer index actually tell us? Accessed March 2016, from http://blogs.bmj.com/bmj/2016/02/09/what-if-anything-does-the-eurohealth-consumer-index-actually-tell-us/.
Booz & Company. (2013). Pharma emerging markets 2.0: How emerging markets are driving the transformation of the pharmaceutical industry. PwC Report. Accessed March 2016, from http://www.strategyand.pwc.com/media/file/Strategyand_Pharma-Emerging-Markets-2.0.pdf.
BPI. (2013). Pharma data 2013. German Pharmaceutical Industry Association. Accessed March 2016, from http://www.bpi.de/fileadmin/media/bpi/Downloads/Internet/Publikationen/Pharma-Daten/Pharmadaten_2013_EN.pdf.
Brammer, S., & Pavelin, S. (2004). Building a good reputation. European Management Journal, 22(6), 704–713.
Business Week. (2007). Drug marketing: will pharma finally have to fess UP? October 8th, Business Week, cited in Crane and Matten, 2007.
Campbell, D. J. (2000, March). Legitimacy theory or managerial reality construction? Corporate social disclosure in Marks and Spencer Plc corporate reports, 1969–1997. Accounting Forum, 24(1), 80–100.
Carroll, A. B., & Buchholtz, A. K. (2009). Business and society: Ethics and stakeholder management (7th ed.). Mason, OH: Cengage Learning.
CIA. (2015). UK chemical and pharmaceutical industry facts and figures. Chemical Industry Association Report. Accessed March 2016, from http://www.cia.org.uk/Portals/0/20150217%20CIA%20facts%20and%20figures%202015.pdf.
Civitas. (2013). Healthcare systems: Germany. Based on the 2001 Civitas Report by David Green and Benedict Irvine Updated by Emily Clarke (2012) and Elliot Bidgood (2013). Accessed March 2016, from http://www.digitalezorg.nl/digitale/uploads/2015/03/germany.pdf.
Commonwealth Fund. (2014). Mirror, mirror on the wall, 2014 update: How the U.S. health care system compares internationally. Commonwealth Fund Publication. Accessed March 2016, from http://www.commonwealthfund.org/publications/fund-reports/2014/jun/mirror-mirror.
Crane, A., & Matten, D. (2010). Business ethics: A European perspective. New York: Oxford University Press.
CSR Risk Mapping Initiative. (2004). Human rights and business risk in the pharmaceutical and chemical sectors. Accessed October 2004, from www-iblf.org/csr/csrwebassist.nsf.
Delamothe, T. (2008). NHS at 60: Founding principles. British Medical Journal (BMJ), 336, 1216–1218. doi:10.1136/bmj.39582.501192.94.
Deloitte. (2014). Stakeholder engagement. Accessed November 2015, from http://www2.deloitte.com/content/dam/Deloitte/za/Documents/governancerisk-compliance/ZA_StakeholderEngagement_04042014.pdf.
Deloitte. (2015a). 2015 Healthcare outlook UK. Accessed March 2016, from http://www2.deloitte.com/content/dam/Deloitte/global/Documents/Life-Sciences-Health-Care/gx-lshc-2015-health-care-outlook-uk.pdf.
Deloitte. (2015b). 2015 Healthcare outlook Germany. Accessed March 2016, from http://www2.deloitte.com/content/dam/Deloitte/global/Documents/Life-Sciences-Health-Care/gx-lshc-2015-health-care-outlook-germany.pdf.
Donaldson, T., & Preston, L. E. (1995). The stakeholder theory of the corporation: Concepts, evidence, and implications. Academy of Management Review, 20(1), 65–91.
EIU. (2014, June). Industry report healthcare Germany. The Economist Intelligence Unit. Accessed March 2016, from http://www.eiuperspectives.economist.com/healthcare/2015-quality-death-index.
EIU. (2015). Quality of death index 2015: Ranking palliative care across the world. The Economist Intelligence Unit. 6 October 2015. Accessed March 2016, from http://www.eiuperspectives.economist.com/healthcare/2015-quality-death-index.
Elkington, J. (1997). Cannibals with forks: The triple bottom line of 21st century business. Oxford: Capstone Publishing.
Esomar. (2006). Piloting the storm: Pharmaceutical industry and public opinion in emerging markets. Healthcare Report. Esomar. Accessed March 2016, from https://directory.esomar.org/moreinfo/1424/Healthcare-Piloting-the-storm.pdf.
Ethical Corp. (2009). If Roche sneezes the pharmaceutical industry catches a cold. Accessed September 2009, from www.ethicalcorp.com.
Ferrell, O. C., Fraedrick, J., & Ferrell, L. (2010). Business ethics: Ethical decision-making and cases. Boston, MA: Centage Learning.
Finance Maps. (2016). German pharmaceutical companies. Accessed March 2016, from http://finance.mapsofworld.com/company/pharmaceutical/germany.html.
Fischer, G. (1964). Allgemeine Betriebwirtschaftslehre [General Business Education] (9th ed.). Heidelberg.
Forbes. (2006). Pill pushers: How the drug industry abandoned science for salesmanship. May 8th, 94–102.
Forbes. (2014). Best of the biggest: How profitable are the world’s largest companies? Forbes. 13th May, 2014. Accessed March 2016, from http://www.forbes.com/sites/liyanchen/2014/05/13/best-of-the-biggest-how-profitable-are-the-worlds-largest-companies/#14e954ba4c33.
Forbes. (2015). Pharma and healthcare. Forbes. 23 March, 2015. Accessed March 2016, from http://www.forbes.com/sites/johnlamattina/2015/03/23/big-pharma-but-not-such-big-money/#24948cb63189.
Fürst, M., & Wieland, J. (2004). WerteManagementSysteme in der Praxis: Erfahrungen und Ausblicke [Values Management Systems in Practice: Experience and Outlook]. In Handbuch Werte Management [Value Management Handbook] (pp. 349–391). Hamburg: Murmann Verlag GmbH.
Get Ethical-Ethical Matters. (2004). Hot topics—GlaxoSmithKline. Accessed October 2004, from www.ethicalmatters.co.uk.
GKV-Vergleich. (2016). So finden Sie die beste gesetzliche Krankenkasse. Accessed March 14, 2016, from http://www.finanztip.de/gkv/.
Grant, R. M. (2006). Contemporary strategy analysis. London: Blackwell.
Gray, R. H., Kouhy, R., & Lavers, S. (1995). Corporate social and environmental reporting: A review of the literature and a longitudinal study of UK disclosure. Accounting, Auditing, and Accountability Journal, 8(2), 47–77.
Grosios, K., Gahan, P. B., & Burbidge, J. (2010). Overview of healthcare in the UK. The EPMA Journal, 1(4): 529–534. Published online 2010 Oct 25. doi:10.1007/s13167-010-0050-1. Accessed March 2016, from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405352/.
Habisch, A., Jonker, J., Wegner, M., & Schmidpeter, R. (2005). Corporate social responsibility. Berlin: Springer.
Haniffa, R. M., & Cooke, T. E. (2005). The impact of culture and governance on corporate social reporting. Journal of Accounting and Public Policy, 24(5), 391–430.
Haugh, R. (2003). Getting the attention of big pharma. Hospitals & Health Networks, 77(10), 44.
Hooper, C.L. (2016). Pharmaceuticals: Economics and regulation. Library of Economics and Liberty. Accessed March 2016, from http://www.econlib.org/library/Enc/PharmaceuticalsEconomicsandRegulation.html.
IFPMA. (2009). International federation of pharmaceutical manufacturers associations. Accessed September 2009, from www.responsiblepractice.com/english/insight/ifpma.
ISO. (2010). Guidance on social responsibility international organisation for standardisation, international standard ISO/DIS 26000, Geneva, Switzerland.
Klein, N. (2000). No logo: Taking aim at the brand bullies. London: Flamingo.
Kröher, M. (2007). Gute Nachbarn [Good Neighbours]. Trends in Good Company Ranking. Manager Magazin, 76, January Issue.
Kurucz, E., Colbert, B., & Wheeler, D. (2008). The business case for corporate social responsibility. In A. Crane, A. McWilliams, D. Matten, J. Moon, & D. Siegel (Eds.), The Oxford handbook of corporate social responsibility (pp. 83–112). Oxford: Oxford University Press.
Lindblom, C. K. (1994). The implications of organisational legitimacy for corporate social performance and disclosure. Paper presented at the Critical Perspectives on Accounting Conference, New York.
Maignan, I., & Ferrell, O. (2003). Nature of corporate responsibilities: Perspectives from American, French, and German consumers. Journal of Business Research, 56, 55–67.
Mallenbaker. (2004). Corporate social responsibility—What does it mean?. Accessed October 2004, from www.mallenbaker.net/csr/csrfiles/definition.htlm.
Mallin, C. A. (2013). Corporate governance (4th ed.). Oxford: Oxford University Press.
Marsh, N. (2013). Investment behaviour and CSR: Utilizing existing mind-sets to leverage sustainable business. Master Thesis, University of Applied Sciences, (FOM), Cologne, Germany.
May, S., Cheney, G., & Roper, J. (2007). The debate over corporate responsibility. Oxford: Oxford University Press.
McDonough, W., & Braungart, M. (2002). Design for the triple top line: New tools for sustainable commerce. Corporate Environmental Strategy, 9(3), 251–258. doi:10.1016/S1066-7938(02)00069-6.
MIIG. (2016). Chemicals and pharmaceuticals: A world class industry. Make it in Germany. Accessed March 2016, from http://www.make-it-in-germany.com/en/for-qualified-professionals/working/industry-profiles/chemicals-and-pharmaceuticals.
Miles, M. P., Munilla, L. S., & Covin, J. G. (2002). The constant gardener revisited: The effect of social blackmail on the marketing concept, innovation, and entrepreneurship. Journal of Business Ethics, 41(3), 287–295.
MSH. (2016). Management sciences for health. Mission and vision. Accessed March 2016, from https://www.msh.org/about-us/mission-and-vision.
Newsaic. (2001). Worldwide incidence and prevalence rates. Accessed October 15, 2004, from www.newsaic.com/mwaids.html.
O’Riordan, L. (2006). CSR and stakeholder dialogue: Theory, concepts, and models for the pharmaceutical industry. MRES Dissertation University of Bradford, Bradford, UK.
O’Riordan, L. (2010). Perspectives on Corporate Social Responsibility (CSR): Corporate approaches to stakeholder engagement in the pharmaceutical industry in the UK and Germany. PhD Thesis, Bradford University School of Management, Bradford, UK.
O’Riordan, L., & Fairbrass, J. (2008). CSR—Theories, models and concepts in stakeholder dialogue—A model for decision-makers in the pharmaceutical industry. Journal of Business Ethics, 83(4), 754–758.
O’Riordan, L., & Fairbrass, J. (2016). Responsible stakeholder engagement: A comparison of corporate approaches in the UK and German pharmaceutical industry. In L. O’Riordan & P. Zmuda (Eds.), FOM KCC KompetenzCentrum für Corporate Social Responsibility der FOM Hochschule für Oekonomie & Management. Band 2.
OECD. (2001). Competition and regulation issues in the pharmaceutical industry. OECD Report. Accessed March 2016, from http://www.oecd.org/competition/sectors/1920540.pdf.
OECD. (2014). Public expenditure on health: As a percentage of total expenditure health. Accessed March 2016, from http://www.oecd-ilibrary.org/social-issues-migration-health/public-expenditure-on-health_20758480-table3.
OECD. (2015). Health expenditure. Accessed March 2016, from http://www.oecd.org/els/health-systems/health-expenditure.htm.
Peters, A., & Roess, D. (2010). The role of governments in promoting corporate responsibility and private sector engagement in development. UN Global Compact and Bertelsmann Stiftung, USA and Germany.
Pharmaceutical Technology. (2015). Pharma mergers: Big business, bad science?. Accessed August 2016, from http://www.pharmaceutical-technology.com/features/featurepharma-mergers-big-business-bad-science-4467897/.
Phillips, R. (2003). Stakeholder theory and organizational ethics. San Francisco, CA: Berrett-Koehler Publishers.
Porter, M. E., & Kramer, M. (2006). Strategy & society: The link between competitive advantage and corporate social responsibility. Harvard Business Review, 84(12), 78–92.
Porter, M. E., & Kramer, M. (2011). Creating shared value: How to reinvent capitalism and unleash a wave of innovation and growth. Harvard Business Review, 89(January–February), 62–77.
PriceWaterhouseCoopers. (2006). Corporate responsibility in the pharmaceutical industry. Price Waterhouse Coopers Website. Accessed May 2004, from www.pwc.com.
PWC. 2016. New regulations bring new risks to life sciences firms. Price Waterhouse Coopers Website. Accessed March 2016, from http://www.pwc.com/us/en/health-industries/pharma-life-sciences/regulatory-risk-compliance.html.
Quist-Arcton, O. (2001). Drugs giants drop case against South Africa. Accessed September 2009, from www.AllAfrica.com, Johannesburg.
Reich, R. (2007). Supercapitalism: The battle for democracy in an age of big business. Cambridge: Icon Books.
Rifkin, J. (2005). Ultimate therapy. Harvard International Review, 27(1), 44–49.
Roddick, A. (2000). Business as unusual. London: Thorsons Publishers.
Rosewitz, B., & Webber, D. (1990). Reformversuche und Reformblokaden im Deutschen Gesundheitswesen [Reform Attempts and Reform Blockages in the German Health System]. Frankfurt: Campus.
Sauerborn, R., & Bäringhausen, T. (2002). One hundred and eighteen years of the German health insurance system: Are there any lessons for middle-and low-income countries. Social Science & Medicine, 54, 1559–1587. Accessed March 2016, from http://www.ministerial-leadership.org/sites/default/files/resources_and_tools/10%20german%20health%20insu.pdf.
Silberhorn, D., & Warren, R. C. (2007). Defining corporate social responsibility: A view from big companies in Germany and the UK. European Business Review, 19(5), 352–372.
Spinello, R. A. (1992). Ethics, pricing and the pharmaceutical industry. Journal of Business Ethics, 11(8), 617–626.
Stark, A. (1994). What’s the matter with business ethics? Harvard Business Review, May–June, 38–48.
Statistica. (2016). Facts on the pharmaceutical industry worldwide. Accessed March 2016, from http://www.statista.com/topics/1764/global-pharmaceutical-industry/.
The Economist. (2004). Business trials and tribulations: Pharmaceuticals, 19 June 2004, p. 74.
The Economist. (2014). Pharmaceutical pricing: The new drugs war. The Economist, 4 January, 2014. Accessed March 2016, from http://www.economist.com/news/leaders/21592619-patents-drugs-are-interests-sick-well-industry-protection-should-not.
The Guardian. (2008). Parallel trade in drugs puts EU patients at risk. The Guardian, 29 June, 2008. Accessed March 2016, from http://www.theguardian.com/business/2008/jun/29/pharmaceuticals.
The Guardian. (2011). How European nations run nation health services. The Guardian, 11 May, 2011. Accessed March 2016, from http://www.theguardian.com/healthcare-network/2011/may/11/european-healthcare-services-belgium-france-germany-sweden.
The Guardian. (2015). UK cancer survival rates trail 10 years behind other European countries. The Guardian, 24 March, 2015. Accessed March 2016, from http://www.theguardian.com/society/2015/mar/24/uk-cancer-survival-rates-trail-10-years-behind-those-in-european-countries.
Third World Network. (2004). Third world network: Aids activists march against pharmaceutical companies. Accessed October 2004, from www.twnside.org.sg.
Time. (2004). Curbing the drug makers. Time Magazine, 5 July 2004, pp. 40–42.
UK Statistics Office. (2015). Accessed March 2016, from http://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthcaresystem/articles/expenditureonhealthcareintheuk/2015-03-26.
Ulrich, V. (1996). Health care in Germany: Structure, expenditure and prospects. In W. McArthur, C. Ramsay, & M. Walker (Eds.), Healthy incentives: Canadian health reform in an international context. Vancouver: The Fraser Institute.
Ulrich, P., & Fluri, E. (1995). Management: Eine Konzentrierte Einführung (Management a Concise Introduction) (7th ed.). Haupt (Bern/Stuttgart/Wien).
VFA. (2005). Verband der forschende Pharma-Unternehmen [Club of Research-Orientated German Pharmaceutical Companies]. Accessed June 2005, from www.fs-arzneimittelindustrie.de.
VFA. (2010). Verband der forschende Pharma-Unternehmen [Club of Research-Orientated German Pharmaceutical Companies]. Accessed February 2010, from www.fs-arzneimittelindustrie.de.
VFA. (2013). Verband der forschende Pharma-Unternehmen [Club of Research-Orientated German Pharmaceutical Companies]. Accessed December 2013, from http://www.vfa.de/.
Wagner, G. R. (2006). Gesellschaftliche Verantwortung als Unternehmensbild? [Social Responsibility as a Corporate Philosophy]. Kapital und Moral in Susanne Hilger. Köln/Cologne (Böhlau).
WHO. (2005). Social health insurance: Key factors affecting he transition towards universal coverage. World Health Organisation, Geneva. Paper written by Guy Carrin and Chris James. Accessed March 2016, from http://www.who.int/health_financing/documents/shi_key_factors.pdf.
WHO. (2016a). Pharmaceutical industry. Accessed March 2016, from http://www.who.int/trade/glossary/story073/en/.
WHO. (2016b). Pharmaceutical industry. Accessed March 2016, from http://apps.who.int/medicinedocs/documents/s16198e/s16198e.pdf.
Woodward, D., Edwards, P., & Birkin, F. (2001). Some evidence on executives: Views of corporate social responsibility. British Accounting Review, 33, 357–397.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
O’Riordan, L. (2017). Case Study on Stakeholder Relationships. In: Managing Sustainable Stakeholder Relationships. CSR, Sustainability, Ethics & Governance. Springer, Cham. https://doi.org/10.1007/978-3-319-50240-3_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-50240-3_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-50239-7
Online ISBN: 978-3-319-50240-3
eBook Packages: Business and ManagementBusiness and Management (R0)